Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C

  • Technology appraisal guidance
  • TA106
  • Published: 
  • Last updated: 
Download guidance (PDF)

Appendix B. Sources of evidence considered by the Committee

A. The assessment report for this appraisal was prepared by Southampton Health Technology Assessment Centre.

Shepherd J, Jones J, Hartwell D, et al. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C – a systematic review and economic evaluation, October 2005

B. The following organisations accepted the invitation to participate in this appraisal. They were invited to make submissions and comment on the draft scope, assessment report and the appraisal consultation document. Consultee organisations are provided with the opportunity to appeal against the final appraisal determination.

I) Manufacturer/sponsors:

  • Roche Products

  • Schering-Plough

II) Professional/specialist and patient/carer group:

  • Action on Hepatitis C

  • Association of Nurses in Substance Abuse

  • British Association for the Study of the Liver

  • British Society of Gastroenterology

  • Children's Liver Disease Foundation

  • Department of Health

  • Haemophilia Alliance

  • Haemophilia Society

  • Hepatitis C Trust

  • Hepatitis Nurse Specialist Forum

  • Mainliners

  • Royal College of General practitioners

  • Royal College of Nursing

  • Royal College of Physicians

  • Transplant Support Network

  • UK Coalition of people Living with HIV and AIDS

  • Welsh Assembly Government

III) Commentator organisation (without the right of appeal):

  • British National Formulary

  • Foundation for Liver Research (formerly the Liver Research Trust)

  • Health Protection Agency

  • MRC Clinical Trials Unit

  • National Coordinating Centre for Health Technology Assessment

  • National Public Health Service for Wales

  • NHS Quality Improvement Scotland

  • Southampton Health Technology Assessment Centre (SHTAC)

C. The following individuals were selected from clinical expert and patient advocate nominations from the professional/specialist and patient/carer groups. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the appraisal consultation document.

  • Professor G Foster, clinical expert, nominated by the Haemophilia Society

  • Mr C Gore, patient expert, nominated by the Hepatitis C Trust

  • Mr J Morris, patient expert, nominated by the Haemophilia Society

  • Mr P Maulayah, clinical expert, nominated by the Hepatitis Nurse Specialist Forum